Nipent pentostatin: Phase I data; marketed to treat hairy cell leukemia

Among 14 evaluable patients with chronic lymphocytic leukemia (CLL) in a 21-patient Phase I trial, the combination of Nipent and cyclophosphamide gave an overall response rate of 71 percent, with 22 p...